SCHEMBL25796958

SCHEMBL25796958

COCCOc1cc(C(F)(F)F)ccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 4/20 0.42
HSD17B10 Q99714 2/20 0.42
HPGD P15428 2/20 0.42
MEN1 O00255 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
PKM P14618 1/20 0.40
TSHR P16473 1/20 0.40
LIPE Q05469 6/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
SCN8A Q9UQD0 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601625 0.88 MAPT (0.37) KDM4EHTTKMT2AALDH1A1HSD17B10
SCHEMBL29276144 0.88 LIPE (0.36) KDM4EHTTKMT2AALDH1A1HSD17B10
SCHEMBL10076681 0.81 L3MBTL1 (0.39) KDM4EHTTKMT2AALDH1A1HPGD
SCHEMBL984465 0.80 SNCA (0.37) KDM4EALDH1A1L3MBTL1
SCHEMBL31020087 0.80 SLC6A4 (0.47) LIPE
SCHEMBL17393177 0.79 AR (0.34) KDM4EHTTKMT2AALDH1A1HSD17B10
SCHEMBL15011434 0.77 CYP1A2 (0.37) LIPE
SCHEMBL27198383 0.77 LIPE (0.35) KDM4EHTTKMT2AALDH1A1HSD17B10
SCHEMBL30129568 0.77 LPL (0.34) KDM4EHTTKMT2A
SCHEMBL29534512 0.76 LPL (0.37) HTTALDH1A1HPGDMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof BEIGENE SWITZERLAND GMBH (CH) 2025-05-15 US disclosed
EP-4448513-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BeiGene Switzerland GmbH (CH) 2024-10-23 EP disclosed
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 WO disclosed
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof STING1, IRF3, MAVS KDM4E 2570/4885HTT 4338/4885KMT2A 3703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.